Fig. 5

NK cell receptors in control, moderate and severe CFS/ME participant groups. a Percentage of total CD56^brightCD16^dim NK cells expressing the receptor NKG2D. b Percentage of total CD56^dimCD16⁻ NK cells expressing the receptor KIR2DL2/DL3. Data is shown as mean ± SEM where statistical significance was accepted as p < 0.05. NK Natural Killer, CFS/ME Chronic Fatigue Syndrome/Myalgic Encephalomyelitis, SEM standard error of the mean